Registered title, quoted from ClinicalTrials.gov
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Fujian Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead (inferred)First Affiliated Hospital of Fujian Medical University福建医科大学附属第一医院FuzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07491263, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
14 years to Not stated; sex: all
Registered eligibility fields
Cytology or histology confirms tumor cell immunophenotype as CD19-positive;
Inclusion criterion 8
Failure to achieve CR after 2 cycles of standard chemotherapy;
Inclusion criterion 3
Toxicity from prior anti-tumor therapy ≤ Grade 1 (according to CTCAE v5.0) or at an acceptable level per inclusion/exclusion criteria;
Inclusion criterion 13
Pregnant or lactating women, or women who disagree to use effective contraception during treatment and within 1 year after treatment;
Exclusion criterion 2
Patients who have received allogeneic immune cell therapy within 6 months before enrollment, or donor lymphocyte infusion within 6 weeks before enrollment;
Exclusion criterion 5
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
Inclusion criterion 10
Key organ functions meeting the following criteria: left ventricular ejection fraction ≥50% by echocardiography; serum creatinine ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN; total bilirubin ≤1.5 × ULN;
Inclusion criterion 11
Negative pregnancy test for women of childbearing potential; both males and females agree to use effective contraception during treatment and for 1 year thereafter;
Inclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07491263, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age > 14 years, gender unrestricted;
- Clinically diagnosed with relapsed/refractory acute B-lymphoblastic leukemia, with bone marrow blast/immature lymphocyte proportion ≥5% (morphology) (excluding cases with isolated extramedullary involvement), meeting any of the following criteria:
- Failure to achieve CR after 2 cycles of standard chemotherapy;
- Initial induction achieved CR, but CR duration ≤12 months;
- Relapsed/refractory B-ALL refractory to first or multiple salvage therapies;
- Post-hematopoietic stem cell transplantation relapse, including hematological relapse and minimal residual disease (MRD) positivity;
- Patients for whom no standard therapy exists.
- Cytology or histology confirms tumor cell immunophenotype as CD19-positive;
- Expected survival time exceeding 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
- Key organ functions meeting the following criteria: left ventricular ejection fraction ≥50% by echocardiography; serum creatinine ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN; total bilirubin ≤1.5 × ULN;
- Negative pregnancy test for women of childbearing potential; both males and females agree to use effective contraception during treatment and for 1 year thereafter;
- Toxicity from prior anti-tumor therapy ≤ Grade 1 (according to CTCAE v5.0) or at an acceptable level per inclusion/exclusion criteria;
- No significant hereditary diseases;
- Able to comprehend the trial requirements and procedures, and willing to participate in the clinical study as required;
- Signed informed consent form for the trial
Exclusion Criteria:
- Presence of central nervous system (CNS) involvement or a clinically significant history of CNS diseases, such as epilepsy and cerebrovascular diseases;
- Pregnant or lactating women, or women who disagree to use effective contraception during treatment and within 1 year after treatment;
- Other malignancies that are not in remission;
- Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy;
- Patients who have received allogeneic immune cell therapy within 6 months before enrollment, or donor lymphocyte infusion within 6 weeks before enrollment;
- Confirmed positive anti-FMC63 and DSA responses in the patient's serum;
- Patients who have participated in other clinical trials within 4 weeks before enrollment;
- Uncontrolled infectious diseases or other serious conditions, including but not limited to infections (human immunodeficiency virus, acute or chronic active hepatitis B or C), congestive heart failure, unstable angina, arrhythmia, or conditions considered by the treating physician to pose unpredictable risks;
- History of stroke or intracranial hemorrhage within 3 months before enrollment;
- Major surgery or trauma within 28 days before enrollment, or main side effects not yet recovered;
- History of allergy to any component of the cell product;
- Inability to understand or unwillingness to sign the informed consent form;
- Other reasons deemed by the researchers as unsuitable for the clinical trial.
Quoted from ClinicalTrials.gov, NCT07491263, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07491263, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.